← Back to headlines
Supernus outlines 2026 revenue outlook and ONAPGO filing target
Supernus Pharmaceuticals has provided an outlook for its 2026 revenue, projecting between $840 million and $870 million, and is targeting a Q3 filing for ONAPGO as a second supplier. This update offers insights into the company's financial expectations and product development timeline.
6 May, 02:22 — 6 May, 02:22
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Agricultural Company Files Cyberlibel, Defamation Complaints Against Farmers' Groups
just now
Philippine ERC suspends electricity disconnections amid rising costs
just now
Oriental Mindoro Jeepney Drivers Receive Government Cash Aid
just now